Compugen Ltd. (CGEN)

NCM – Цена в реальном времени. Валюта: USD

2.83

-0.04 (-1.39%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.85

+0.02 (0.71%)

До открытия: May 13, 2026, 8:43 AM EDT

12.05.2026

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 Stifel Virtual Targeted Oncology Forum.

04.05.2026

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open.

09.04.2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference.

02.03.2026

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen remains a 'Buy,' supported by pipeline progress, major pharma partnerships, and a cash runway extended into 2029. Key catalysts include the phase 3 MAIA-Ovarian cancer trial (COM701), with interim analysis expected in Q1 2027, and the anti-IL18BP antibody GS-0321 in phase 1. CGEN's non-dilutive deal with AstraZeneca monetizes rilvegostomig royalties, enhancing financial stability and preserving future upside.

02.03.2026

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

02.03.2026

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago.

02.03.2026

Compugen Reports Fourth Quarter and Full Year 2025 Results

Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leadership team with Dr. Eran Ophir appointed President and CEO and Dr. Anat Cohen-Dayag transitioned to Executive Chair Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively On track to have MAIA-ovarian interim analysis in Q1 2027 Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with 10 ongoing Phase 3 clinical trials, and anticipates further Phase 1/2 clinical trial data with rilvegostomig in 2026 HOLON, ISRAEL, March 2, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today reported financial results for the fourth quarter and full year 2025 and provided a corporate update.

Видео

No Data

There is no data to display

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D.

Compugen Ltd. (CGEN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Compugen Ltd. (CGEN)

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen Reports Fourth Quarter and Full Year 2025 Results

Видео

No Data

Пресс-релизы

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen Reports Fourth Quarter and Full Year 2025 Results

Видео

No Data

Пресс-релизы

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Search stocks

Compugen Ltd. (CGEN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Compugen Ltd. (CGEN)

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen Reports Fourth Quarter and Full Year 2025 Results

Видео

No Data

Пресс-релизы

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen Reports Fourth Quarter and Full Year 2025 Results

Видео

No Data

Пресс-релизы

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors